Arvinas (ARVN) Projected to Post Quarterly Earnings on Tuesday

Arvinas (NASDAQ:ARVN) is expected to post its quarterly earnings results before the market opens on Tuesday, February 25th. Analysts expect Arvinas to post earnings of ($1.07) per share and revenue of $62.79 million for the quarter. Individual that wish to listen to the company’s earnings conference call can do so using this link.

Arvinas (NASDAQ:ARVN) last posted its earnings results on Tuesday, February 11th. The company reported ($0.63) EPS for the quarter, beating analysts’ consensus estimates of ($1.07) by $0.44. Arvinas had a negative return on equity of 33.75% and a negative net margin of 75.51%. During the same period in the prior year, the company earned ($2.53) EPS. On average, analysts expect Arvinas to post $-4 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Arvinas Stock Down 3.3 %

NASDAQ:ARVN opened at $17.77 on Friday. Arvinas has a 52 week low of $16.61 and a 52 week high of $51.51. The company has a market capitalization of $1.22 billion, a P/E ratio of -6.42 and a beta of 1.88. The stock’s fifty day moving average is $18.49 and its two-hundred day moving average is $22.92.

Analyst Upgrades and Downgrades

Several equities research analysts recently issued reports on ARVN shares. Barclays cut their price objective on Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a report on Monday, February 3rd. Stephens initiated coverage on Arvinas in a report on Monday, November 18th. They issued an “overweight” rating and a $55.00 price objective on the stock. Oppenheimer boosted their target price on Arvinas from $40.00 to $45.00 and gave the stock an “outperform” rating in a research note on Wednesday, February 12th. Wedbush reissued an “outperform” rating and set a $57.00 target price on shares of Arvinas in a research note on Tuesday, February 11th. Finally, Cantor Fitzgerald reissued an “overweight” rating on shares of Arvinas in a research note on Friday, February 7th. Twelve equities research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock presently has a consensus rating of “Buy” and an average price target of $60.00.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.